Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veradermics, Incorporated Common Stock (NY:MANE)

131.55 -3.74 (-2.76%)
Delayed Quote Updated: 10:56 AM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Veradermics, Incorporated Common Stock

< Previous 1 2 Next >
News headline image
Veradermics to Present at the Jefferies Global Healthcare Conference in London
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
News headline image
Why This Hair Restoration Biotech's Shares Are Soaring ↗
Veradermics' shares are up nearly 270% since its IPO earlier this year. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results ↗
Veradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild... 
Via MarketBeat
News headline image
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 ‘304’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Present at Upcoming September Investor Conferences
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women ↗
Veradermics (NYSE:MANE) said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a... 
Via MarketBeat
News headline image
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Present at Upcoming June Investor Conferences
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
From Veradermics, Incorporated
Via Business Wire
News headline image
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO ↗
Veradermics develops novel dermatology treatments, targeting both adult and pediatric markets with a research-driven approach. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Launch of Public Offering
From Veradermics, Incorporated
Via Business Wire
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
From Veradermics, Inc.
Via Business Wire
News headline image
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
From Veradermics, Incorporated
Via Business Wire
News headline image
Veradermics to Participate in Upcoming March Investor Conferences
From Veradermics, Incorporated
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>